CHENNAI, March 7, 2013 /PRNewswire/ -- For its ability to unblock and then make arteries return to natural form, the recently launched bioresorbable vascular scaffold (BVS and also known as disappearing stent) is being hailed as the 4th revolution in management of coronary artery disease at India's biggest conference on interventional cardiology that took place at Hotel ITC Grand Chola, Chennai from February 27 to March 2, 2013.
Dr. Samin K. Sharma , Director, Clinical & Interventional Cardiology, Mount Sinai Medical Center, New York said, "If BVS is used in the treatment of coronary artery disease, the long term benefits are huge. Since the stent will leave body after 2 years after doing its work of clearing blockages, patient will not have to take blood thinning medicines lifelong and the vessels can return to its natural form making it work as per body needs. It is nothing less than a dream come true."
According to Dr. Mathew Samuel , father of Angioplasty, and Dr. Antonio Colombo , famously known as world leader in interventional cardiology from Italy, angioplasty with conventional stents has always carried the fear of clot because of stent called late stent thrombosis.
This is seen in about 10% of patients after 1 or 2 years. This problem is expected to be less if BVS is used.
"Unlike western world, the prevalence of heart disease is significantly high among young people in India. For these people, the dissolving stent is a blessing as they will no longer have to worry about any alteration in natural artery structure in their long life ahead," added Dr. Sharma
BVS or Absorb is a first-of-its-kind device for the treatment of coronary artery disease (CAD). It works by restoring blood flow to the heart similar to a metallic stent, but then dissolves into the body, leaving behind a treated vessel that may resume more natural function and movement.
The potential long-term benefits of a scaffold that dissolves are significant.
The vessel may expand and contract as needed to increase the flow of blood to the heart in response to normal activities such as exercising; treatment and diagnostic options are broadened; the need for long-term treatment with anti-clotting medications may be reduced; and future interventions would be unobstructed by a permanent implant.
Absorb is supported by a robust clinical trial program that encompasses five studies in more than 30 countries around the world and is approved for use by Drug Controller General of India.
About India Live Cardiology:
India Live is a cardiology meeting which focuses on the specialized field of interventional cardiology. This meet has been designed to bring together experts from 35 different countries, all masters in their field to impart knowledge and discuss experiences with more than 1800 Indian delegates. We will be having live case presentations and interventional procedures from the top cardiac centers all over India and also internationally. This meeting will help doctors to integrate their practical experiences with that being followed internationally and assist them in developing their skills. All this will eventually culminate in higher standards of patient care and lead to benefitting the medical practice in the Indian scenario.
India Live in its 4th year running and with every year we have been getting higher and higher responses from the medical fraternity. This year at Chennai we have had the largest response so far. We have also paid attention to younger colleagues of our field by dedicating a whole day of seminars and case discussions solely designed for them. This is called our Fellows program. To support this endeavour, renowned teachers from the American college of cardiology, European Cardiologic society, CCT and numerous other compatriot societies have extended their know how.